Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR1 |
Variant | S125L |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | FGFR1 S125L lies within the extracellular domain of the Fgfr1 protein (UniProt.org). S125L results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR1 mutant FGFR1 S125L |
Transcript | NM_023110.3 |
gDNA | chr8:g.38428420G>A |
cDNA | c.374C>T |
Protein | p.S125L |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001174063 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001174063.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001174063.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001174065 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001174065.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001174065.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001174066 | chr8:g.38426226_38426227delCTinsAG | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
NM_001174066.1 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
NM_001174066.2 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
NM_001354367.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001354367.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001354369.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001354369.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_001410922.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_015850 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_015850.3 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_015850.4 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_023105 | chr8:g.38426226_38426227delCTinsAG | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
NM_023105.2 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
NM_023105.3 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
NM_023110 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_023110.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
NM_023110.3 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716303 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716303.3 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716303.4 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716304 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716304.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716304.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716306 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716307 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716307.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716307.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716310 | chr8:g.38426226_38426227delCTinsAG | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716310.3 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716310.4 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716311 | chr8:g.38426226_38426227delCTinsAG | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716311.1 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716311.1 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716312 | chr8:g.38426226_38426227delCTinsAG | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716312.2 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_006716312.2 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_011544448 | chr8:g.38428000_38428001delCTinsAG | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_011544448.1 | chr8:g.38428000_38428001delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_011544448.2 | chr8:g.38428000_38428001delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013221 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013221.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013221.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013222 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013222.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013223 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013224 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013224.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013225 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013225.2 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013225.3 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013226 | chr8:g.38428000_38428001delCTinsAG | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013226.1 | chr8:g.38428000_38428001delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_017013226.2 | chr8:g.38428000_38428001delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
XM_047421569.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_047421570.1 | chr8:g.38428420G>A | c.374C>T | p.S125L | RefSeq | GRCh38/hg38 |
XM_047421573.1 | chr8:g.38426226_38426227delAGinsCT | c.373_374delAGinsCT | p.S125L | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 S125L | Advanced Solid Tumor | predicted - sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 S125L | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 S125L | Advanced Solid Tumor | predicted - sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 S125L | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 S125L | Advanced Solid Tumor | predicted - sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 S125L | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 S125L | Advanced Solid Tumor | predicted - resistant | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 S125L were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: